The price of Revelation Biosciences Inc. (NASDAQ:REVB) shares last traded on Wall Street fell -14.66% to $1.63.
Based on available information, 1 analysts follow Revelation Biosciences Inc. (NASDAQ:REVB). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $15.00, we find $15.00. Given the previous closing price of $1.91, this indicates a potential upside of 685.34 percent. REVB stock price is now -70.78% away from the 50-day moving average and -87.20% away from the 200-day moving average. The market capitalization of the company currently stands at $1.12M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $15.00 as their price target over the next twelve months.
.
A total of 59.18% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in REVB stock. A new stake in Revelation Biosciences Inc. shares was purchased by REBALANCE, LLC during the first quarter worth $4,000. In total, there are 16 active investors with 18.50% ownership of the company’s stock.
A candlestick chart of Revelation Biosciences Inc. (NASDAQ: REVB) showed a price of $1.7300 on Wednesday morning. During the past 12 months, Revelation Biosciences Inc. has had a low of $1.55 and a high of $100.80. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.50, and a quick ratio of 1.50. The fifty day moving average price for REVB is $5.4797 and a two-hundred day moving average price translates $12.6455 for the stock.
The latest earnings results from Revelation Biosciences Inc. (NASDAQ: REVB) was released for Sep, 2022.
Revelation Biosciences Inc.(REVB) Company Profile
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
